Sanigen's Q1 2026 Net Loss Narrows to 898M Won, Equity Drops and Debt Ratio Rises
-
Q1 2026 revenue: 3.31B won (down 21.3% YoY from 4.21B won)
-
Operating loss: 0.87B won (improved from 1.19B loss in Q1 2025)
-
Net loss: 0.90B won (improved from 1.62B loss in Q1 2025)
-
Total equity: 1.59B won (down 35.9% from 2.48B at year-end 2025)
-
Net debt ratio: 60.2% (up from 30.3% at year-end 2025)
-
Full allowance of 1.40B won for fraud-related receivables
-
R&D expenses: 0.38B won (11.6% of revenue)
-
Post-report: decided capital increase (~6.57M shares) and 5B won CB issuance
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: SANIGEN (188260)
-
Submission: SANIGEN Co., Ltd.
-
Receipt: 05-14-2026